Get the Stockscreener App
12.59
1.18%
-0.15
After Hours:
12.59
Celcuity Inc stock is traded at $12.59, with a volume of 139.09K.
It is down -1.18% in the last 24 hours and down -4.40% over the past month.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
See More
Previous Close:
$12.74
Open:
$12.85
24h Volume:
139.09K
Relative Volume:
0.51
Market Cap:
$467.46M
Revenue:
-
Net Income/Loss:
$-63.78M
P/E Ratio:
-4.6978
EPS:
-2.68
Net Cash Flow:
$-53.91M
1W Performance:
+7.42%
1M Performance:
-4.40%
6M Performance:
-22.71%
1Y Performance:
-19.91%
1-Day Range:
$12.28
$12.96
1-Week Range:
$11.49
$13.14
52-Week Range:
$10.35
$22.19
Celcuity Inc Stock (CELC) Company Profile
Name
Celcuity Inc
Sector
Industry
Phone
763-392-0767
Address
16305 36TH AVENUE N, MINNEAPOLIS, MN
Compare CELC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
12.59 | 467.46M | 0 | -63.78M | -53.91M | -2.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Feb-22-24 | Initiated | Stifel | Buy |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Oct-08-21 | Initiated | Canaccord Genuity | Buy |
| Sep-07-21 | Initiated | Jefferies | Buy |
| Jul-29-21 | Initiated | Cowen | Outperform |
| Jul-27-21 | Initiated | Needham | Buy |
| Jan-28-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-24-20 | Reiterated | H.C. Wainwright | Buy |
| May-11-20 | Resumed | Craig Hallum | Buy |
| Nov-20-18 | Initiated | H.C. Wainwright | Buy |
View All
Celcuity Inc Stock (CELC) Latest News
Scorpion stinger bringer of more PI3Kα inhibitor deals? - BioWorld Online
BlackRock, Inc. Expands Holdings with Celcuity Inc. Acquisition - GuruFocus.com
(CELC) Technical Data - Stock Traders Daily
JPMorgan Chase & Co. Sells 11,612 Shares of Celcuity Inc. (NASDAQ:CELC) - Defense World
Celcuity to Participate in the Canaccord Genuity 41st Annual Growth Conference - ACCESS Newswire
When (CELC) Moves Investors should Listen - Stock Traders Daily
Jefferies lifts Celcuity stock target to $33, maintains Buy rating - MSN
Jefferies lifts Celcuity stock target to $33, maintains Buy rating By Investing.com - Investing.com Australia
Celcuity Closes $100 Million Private Placement - ACCESS Newswire
Hennion & Walsh Asset Management Inc. Buys 71,006 Shares of Celcuity Inc. (NASDAQ:CELC) - MarketBeat
Celcuity Inc. (NASDAQ:CELC) Receives $29.17 Average PT from Analysts - Defense World
Celcuity Inc. (NASDAQ:CELC) Holdings Raised by Barclays PLC - Defense World
Celcuity Inc. (NASDAQ:CELC) Shares Bought by Barclays PLC - MarketBeat
Celcuity Inc. (NASDAQ:CELC) Receives $29.17 Average PT from Brokerages - MarketBeat
Analyzing Celcuity (NASDAQ:CELC) and CannLabs (OTCMKTS:CANL) - Defense World
Jane Street Group LLC Sells 9,921 Shares of Celcuity Inc. (NASDAQ:CELC) - Defense World
Celcuity stock touches 52-week low at $11.51 amid market challenges - Investing.com Australia
Objective long/short (CELC) Report - Stock Traders Daily
Geode Capital Management LLC Acquires 136,518 Shares of Celcuity Inc. (NASDAQ:CELC) - MarketBeat
Celcuity Inc. (NASDAQ:CELC) Shares Purchased by Geode Capital Management LLC - Defense World
Celcuity Inc. (NASDAQ:CELC) Shares Acquired by Barclays PLC - Defense World
Barclays PLC Raises Stock Position in Celcuity Inc. (NASDAQ:CELC) - MarketBeat
Celcuity (NASDAQ:CELC) Trading Up 3.8%Here's Why - MarketBeat
State Street Corp Purchases 668,318 Shares of Celcuity Inc. (NASDAQ:CELC) - MarketBeat
How to Take Advantage of moves in (CELC) - Stock Traders Daily
Celcuity Inc. (NASDAQ:CELC) Receives $29.17 Consensus Target Price from Analysts - Defense World
Celcuity Inc. (NASDAQ:CELC) Given Average Rating of "Buy" by Analysts - MarketBeat
Wellington Management Group LLP Makes New Investment in Celcuity Inc. (NASDAQ:CELC) - MarketBeat
Mama's Creations Posts Weak Earnings, Joins EVgo, Red Cat Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market SessionCelcuity (NASDAQ:CELC), Apellis Pharmaceuticals (NASDAQ:APLS) - Benzinga
Celcuity (CELC) Charges Forward with Promising Potential Cancer Treatments - TipRanks
Celcuity Inc. (NASDAQ:CELC) Short Interest Update - MarketBeat
Charles Schwab Investment Management Inc. Purchases 153,712 Shares of Celcuity Inc. (NASDAQ:CELC) - Defense World
(CELC) Investment Report - Stock Traders Daily
BNP Paribas Financial Markets Raises Holdings in Celcuity Inc. (NASDAQ:CELC) - MarketBeat
BNP Paribas Financial Markets Has $673,000 Stake in Celcuity Inc. (NASDAQ:CELC) - Defense World
Celcuity reports survival data for breast cancer drug - Investing.com
Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium - The Manila Times
Celcuity Presents Overall Survival Data from Phase 1b Study - GlobeNewswire
Verition Fund Management LLC Reduces Holdings in Celcuity Inc. (NASDAQ:CELC) - MarketBeat
Braidwell LP Buys 367,663 Shares of Celcuity Inc. (NASDAQ:CELC) - MarketBeat
Celcuity Inc. (NASDAQ:CELC) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
(CELC) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Celcuity’s (CELC) “Buy” Rating Reiterated at Needham & Company LLC - Defense World
Celcuity’s (CELC) “Buy” Rating Reiterated at HC Wainwright - Defense World
Celcuity (NASDAQ:CELC) Receives "Buy" Rating from HC Wainwright - MarketBeat
Celcuity stock hits 52-week low at $12.14 amid market shifts - Investing.com
500: Something went wrong - Investing.com India
Earnings call: Celcuity reports Q3 2024 financials and clinical trial updates - Investing.com
Celcuity Inc Stock (CELC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):